FinBoss.io
CSEN
  • Home
  • Crypto prices
  • Bitcoin on-chain
  • US macro
  • US stocks
  • Guides
  • How we make money
FinBoss.io
Home
Crypto prices
Bitcoin on-chain
Hashrate
Mining difficulty
Mining pools
Mempool and fees
On-chain activity
MVRV and NUPL
SOPR
Holders
Supply in profit
Rainbow Chart
Fair value
Pi Cycle Top
US macro
FedWatch
Interest rates
Treasury yields
Inflation
Liquidity and Bitcoin
Business cycle
US stocks
Stock screener
Earnings calendar
Insider trading
Market heatmap
Guides
How we make money
CSEN
Home
Stocks
Biogen Inc
BI

Biogen Inc

BIIBHealth care

Stock · Data from SEC EDGAR 13F · Held by 11 of 87 tracked investors

$250.69
▼ 1.24%
Famous investorshold 11buying 1selling 0
Price (USD)
$250.69
Market cap
$37B
P/E ratio
44.5
Tracked investors holding
11 of 87
Next earnings
28 Oct 2026

Biogen Inc at a glance

An overview of the financial statements, in plain language. Switch to the advanced view for charts.

FinBoss score
55out of 100
  • Valuation27
  • Growth33
  • Profitability71
  • Quality62
  • Debt48
  • Stability87
In its favour
  • Nothing notable from the statements.

Earnings results

QuarterReportedEPSAnalyst estimateSurprise
Jun 202629 Jul 20263.603.04+18.4%
Mar 202629 Apr 20263.572.95+21%
Dec 20256 Feb 20261.991.61+23.6%
Sep 202530 Oct 20254.813.89+23.7%

EPS is earnings per share. The surprise is the difference against the analysts' consensus. Source: Nasdaq, in dollars.

7D
+7.75%
1M
+10.75%
3M
+23.99%
YTD
+40.98%
1Y
+67.25%
3Y
+6.89%
5Y
-6.00%
Forward P/E
15.2
Dividend yield
–
52-week low
$138.00
52-week high
$254.41

Chart BIIB

Insider purchases

last 90 days, SEC Form 4
Loading insider trades…

Which investors hold this stock

11
SM
Samantha McLemore
Patient Capital Management
2.01%$61,295,674▼ -25.3%
GI
Generali Investments CEE
Generali Investments CEE
0.45%$9,409,845unchanged
CA
Cliff Asness
AQR Capital Management
0.15%$416,928,075▲ +0.7%
JG
Joel Greenblatt
Gotham Asset Management
0.14%$60,475,194▼ -6.2%
Ns
Norský státní fond
Norges Bank
0.06%$557,441,930New position
Šn
Švýcarská národní banka
Swiss National Bank
0.05%$89,427,234▼ -3.9%
Čn
Česká národní banka
Česká národní banka
0.05%$9,589,284▲ +1%
JS
Jim Simons
Renaissance Technologies
0.02%$16,797,369▼ -61.8%
SC
Steven Cohen
Point72 Asset Management
0.02%$19,045,473▼ -89.1%
KF
Ken Fisher
Fisher Investments
0.02%$73,032,374▲ +8.1%
KG
Ken Griffin
Citadel Advisors
0.01%$90,389,997▲ +203%

Frequently asked questions

How much is Biogen Inc (BIIB) stock?

Biogen Inc shares trade at $250.69, -1.24% over the last trading day. The price is delayed.

What is the market cap of Biogen Inc?

The market cap of Biogen Inc is about $37B and its price-to-earnings ratio (P/E) is 44.5.

How has Biogen Inc stock performed over the last year?

The Biogen Inc share price changed by +67.25% over 12 months and by -6.00% over 5 years.

Which big investors hold Biogen Inc?

According to the latest 13F filings, 11 of 87 tracked investors hold Biogen Inc, for example Samantha McLemore, Generali Investments CEE, Cliff Asness.

When will Biogen Inc report its next results?

The next earnings report of Biogen Inc is expected on 28 Oct 2026.

Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.

© 2026 FinBoss.io. All rights reserved.

How we make moneyTerms (Czech)Privacy (Czech)Cookies (Czech)

Disclaimer: the information on this site is for general information only and is not investment or financial advice. Investing involves risk, and cryptocurrencies are especially volatile. Past performance does not guarantee future results. Some links are affiliate links and are marked as ads.

What to watch
  • !Net debt is high: at the current free cash flow it would take 5.6 years to repay.
  • !Revenue fell 0.9% a year over 3 years.
  • !The stock is expensive: you pay 44.5 USD for 1 USD of annual earnings.

The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.

Is the stock expensive?

Fairly expensive

For 1 USD of annual earnings you pay 44.5 USD. Based on next year's estimates 15.2 USD.

P/E
44.5×
P/S
3.7×
EV/EBITDA
13.1×

Is the company growing?

Flat
22
23
24
25

Revenue over 3 years grew -0.9% a year. Last year 3.4%.

Does it make money?

Good
  • Cost of sales 24
  • Research 18.0
  • Operations and selling 32.7
  • Taxes and other 11.9
  • Net profit 13.1

Out of 100 USD of revenue, 13.1 USD is left as net profit.

Is it financially healthy?

Mostly
Cash
1.3B USD
Debt
8.4B USD
Free CF
1.3B USD

It could repay its net debt from free cash flow in 5.6 years.

Does it pay a dividend?

No dividend

The company pays no dividend. It reinvests the money or holds it.

What do analysts expect?

Buy
Average target
247.32 USD
Vs price
−1%

32 analysts. Their opinion is not a recommendation by FinBoss.io.

Which big investors hold it?

11 of 87

Among the tracked investors, Samantha McLemore, Generali Investments CEE, Cliff Asness and others hold the stock according to 13F filings.

Revenue and net profit (USD B)

Margins (% of revenue)

Free cash flow and capex (USD B)

Cash and debt (USD B)

Earnings per share (EPS, USD)

Latest quarters (USD B)

Ratios

P/E
44.5×
Forward P/E
15.2×
P/B
2.0×
P/S
3.7×
PEG
2.62
EV/EBITDA
13.1×
Gross margin
78.3%
Operating margin
25.1%
Net margin
8.3%
ROE
4.6%
ROA
5.2%
Debt / equity
0.4×
Current ratio
1.9×
Revenue growth
3.4%
Earnings growth
-84.8%
Beta
0.09
Dividend
0.00%
Payout ratio
0%